Healthcare / Diagnostics & ResearchKOSDAQ
$4040.00
+150.00 (+3.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-7.7B · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$27.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-152.3%
↓Gross Margin
-646.3%
↓Debt/Equity
0.52
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-52.9%
FCF CAGR
—
FCF margin
-1892.7%
FCF / Net income
0.60x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $381.4M · net income $-11.96B · FCF $-7.22B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $381.4M | $381.4M | $1.21B | $897.0M | $3.65B |
| Net Income | $-11.96B | $-11.96B | $-8.92B | $-7.92B | $-9.00B |
| EBITDA | $-14.77B | $-14.77B | $-8.30B | $-7.23B | $-6.58B |
| EPS | -1754.00 | -1754.00 | -1302.00 | -1139.00 | -1303.00 |
| Gross Margin | -646.3% | -646.3% | -150.7% | -176.8% | 32.0% |
| Operating Margin | -2540.1% | -2540.1% | -837.5% | -1057.1% | -180.8% |
| Net Margin | -3135.0% | -3135.0% | -738.2% | -882.4% | -246.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.52 | 0.52 | 0.21 | 0.16 | 0.12 |
| Current Ratio | 2.62 | 2.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.22B | $-7.22B | $-7.70B | $-8.23B | $-6.74B |
| Returns | |||||
| ROE | -152.3% | -152.3% | -46.3% | -28.8% | -25.6% |
| Valuation | |||||
| P/B | 3.51 | 3.51 | 3.73 | 2.63 | 1.68 |
| Growth & Yield | |||||
| Revenue Growth | -68.4% | -68.4% | 34.6% | -75.4% | — |
| EPS Growth | -34.7% | -34.7% | -14.3% | 12.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-59.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1302.00 → -1754.00
Residual
-59.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.